Claire Mazumdar Sells 15,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 15,000 shares of the business’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $23.61, for a total value of $354,150.00. Following the completion of the transaction, the chief executive officer owned 362,152 shares of the company’s stock, valued at $8,550,408.72. This trade represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.84, for a total value of $122,441.16.
• On Thursday, March 19th, Claire Mazumdar sold 6,905 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.78, for a total value of $129,675.90.
• On Friday, March 20th, Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.95, for a total value of $30,244.20.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The stock was sold at an average price of $19.17, for a total value of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total value of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.74, for a total value of $33,469.64.

Bicara Therapeutics Stock Down 1.5%

BCAX stock opened at $23.11 on Wednesday. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -9.13 and a beta of -1.23. The business has a fifty day simple moving average of $18.98 and a 200-day simple moving average of $17.68. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $24.25.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.04. As a group, analysts expect that Bicara Therapeutics Inc. will post -2.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on BCAX shares. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Citizens Jmp restated a “market outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, March 31st. The Goldman Sachs Group upped their price target on shares of Bicara Therapeutics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. Finally, UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Eight research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG boosted its position in Bicara Therapeutics by 0.9% in the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after buying an additional 1,171 shares during the last quarter. Legal & General Group Plc boosted its position in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the last quarter. Mariner LLC boosted its position in Bicara Therapeutics by 3.0% in the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock valued at $1,087,000 after buying an additional 1,902 shares during the last quarter. Invesco Ltd. boosted its position in Bicara Therapeutics by 13.2% in the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after buying an additional 1,962 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Bicara Therapeutics in the 4th quarter valued at about $45,000.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.